GB0119172D0 - Phenyl pyrrole derivatives - Google Patents

Phenyl pyrrole derivatives

Info

Publication number
GB0119172D0
GB0119172D0 GBGB0119172.5A GB0119172A GB0119172D0 GB 0119172 D0 GB0119172 D0 GB 0119172D0 GB 0119172 A GB0119172 A GB 0119172A GB 0119172 D0 GB0119172 D0 GB 0119172D0
Authority
GB
United Kingdom
Prior art keywords
pyrrole derivatives
phenyl pyrrole
phenyl
derivatives
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0119172.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melacure Therapeutics AB
Original Assignee
Melacure Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melacure Therapeutics AB filed Critical Melacure Therapeutics AB
Priority to GBGB0119172.5A priority Critical patent/GB0119172D0/en
Publication of GB0119172D0 publication Critical patent/GB0119172D0/en
Priority to KR10-2003-7016099A priority patent/KR20040019302A/ko
Priority to DK02753136T priority patent/DK1414440T3/da
Priority to MXPA04001037A priority patent/MXPA04001037A/es
Priority to ES02753136T priority patent/ES2280555T3/es
Priority to IL16018102A priority patent/IL160181A0/xx
Priority to NZ529666A priority patent/NZ529666A/en
Priority to JP2003518518A priority patent/JP4450620B2/ja
Priority to SI200230506T priority patent/SI1414440T1/sl
Priority to AU2002313542A priority patent/AU2002313542B2/en
Priority to DE60217503T priority patent/DE60217503T2/de
Priority to US10/484,444 priority patent/US7186748B2/en
Priority to BR0210445-8A priority patent/BR0210445A/pt
Priority to PCT/GB2002/003620 priority patent/WO2003013509A1/en
Priority to PT02753136T priority patent/PT1414440E/pt
Priority to CA2448356A priority patent/CA2448356C/en
Priority to EP02753136A priority patent/EP1414440B1/en
Priority to NO20040465A priority patent/NO20040465L/no
Priority to US11/374,956 priority patent/US7442807B2/en
Priority to CY20071100446T priority patent/CY1106424T1/el
Priority to US12/232,399 priority patent/US20090018183A1/en
Priority to JP2009143997A priority patent/JP2009242414A/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42Nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
GBGB0119172.5A 2001-08-06 2001-08-06 Phenyl pyrrole derivatives Ceased GB0119172D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB0119172.5A GB0119172D0 (en) 2001-08-06 2001-08-06 Phenyl pyrrole derivatives
EP02753136A EP1414440B1 (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
DE60217503T DE60217503T2 (de) 2001-08-06 2002-08-06 N-phenylpyrrol guanidin derivate als melanocortinrezeptor liganden
BR0210445-8A BR0210445A (pt) 2001-08-06 2002-08-06 Derivados de n-fenilpirrol guanidina como ligandos de receptor melanocortin
MXPA04001037A MXPA04001037A (es) 2001-08-06 2002-08-06 Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
ES02753136T ES2280555T3 (es) 2001-08-06 2002-08-06 Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
IL16018102A IL160181A0 (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
NZ529666A NZ529666A (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands
JP2003518518A JP4450620B2 (ja) 2001-08-06 2002-08-06 メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体
SI200230506T SI1414440T1 (sl) 2001-08-06 2002-08-06 N-fenilpirol gvanidinski derivati kot ligandi melanokortinskih receptorjev
AU2002313542A AU2002313542B2 (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands
KR10-2003-7016099A KR20040019302A (ko) 2001-08-06 2002-08-06 멜라노코르틴 수용체 리간드로서의 n-페닐피롤 구아니딘 유도체
US10/484,444 US7186748B2 (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
DK02753136T DK1414440T3 (da) 2001-08-06 2002-08-06 N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
PCT/GB2002/003620 WO2003013509A1 (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands
PT02753136T PT1414440E (pt) 2001-08-06 2002-08-06 Derivados de n-fenilpirrologuanidina como ligandos de receptores de melanocortina
CA2448356A CA2448356C (en) 2001-08-06 2002-08-06 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
NO20040465A NO20040465L (no) 2001-08-06 2004-02-02 N-fenylpyrrolguanidin-derivater som melanokortin-mottagerligander
US11/374,956 US7442807B2 (en) 2001-08-06 2006-03-15 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
CY20071100446T CY1106424T1 (el) 2001-08-06 2007-03-30 Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
US12/232,399 US20090018183A1 (en) 2001-08-06 2008-09-17 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
JP2009143997A JP2009242414A (ja) 2001-08-06 2009-06-17 メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119172.5A GB0119172D0 (en) 2001-08-06 2001-08-06 Phenyl pyrrole derivatives

Publications (1)

Publication Number Publication Date
GB0119172D0 true GB0119172D0 (en) 2001-09-26

Family

ID=9919909

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0119172.5A Ceased GB0119172D0 (en) 2001-08-06 2001-08-06 Phenyl pyrrole derivatives

Country Status (19)

Country Link
US (3) US7186748B2 (https=)
EP (1) EP1414440B1 (https=)
JP (2) JP4450620B2 (https=)
KR (1) KR20040019302A (https=)
AU (1) AU2002313542B2 (https=)
BR (1) BR0210445A (https=)
CA (1) CA2448356C (https=)
CY (1) CY1106424T1 (https=)
DE (1) DE60217503T2 (https=)
DK (1) DK1414440T3 (https=)
ES (1) ES2280555T3 (https=)
GB (1) GB0119172D0 (https=)
IL (1) IL160181A0 (https=)
MX (1) MXPA04001037A (https=)
NO (1) NO20040465L (https=)
NZ (1) NZ529666A (https=)
PT (1) PT1414440E (https=)
SI (1) SI1414440T1 (https=)
WO (1) WO2003013509A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB2398299A (en) * 2003-02-13 2004-08-18 Melacure Therapeutics Ab Pharmaceutically active phenyl-pyrrole derivatives
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
NZ573457A (en) 2006-06-09 2011-06-30 Action Pharma As Phenyl pyrrole aminoguanidine derivatives
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
EP2045250A1 (en) * 2007-09-26 2009-04-08 Action Pharma A/S Ring-substituted phenyl pyrrole aminoguanidine derivatives
WO2009071101A1 (en) * 2007-12-07 2009-06-11 Action Pharma A/S N-modified aminoguanidine derivatives
WO2009074157A1 (en) * 2007-12-13 2009-06-18 Action Pharma A/S Fully-modified phenyl pyrrole aminoguanidines
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
ES2572615T3 (es) 2008-08-15 2016-06-01 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2298541A1 (en) 2009-09-17 2011-03-23 Rieter Technologies AG Moulded automotive part
PT2477802T (pt) 2009-09-16 2018-03-02 Autoneum Man Ag Produto moldado para painéis automóveis
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2502788B1 (en) 2011-03-23 2014-03-12 Autoneum Management AG Production process for a moulded multilayer lining
EP2503040A1 (en) 2011-03-23 2012-09-26 Autoneum Management AG Moulded multilayer lining
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US8434136B1 (en) 2012-11-29 2013-04-30 Jeffry David Aronson Full spectrum cyber identification determination process
US9319414B2 (en) 2012-11-29 2016-04-19 Jeffry David Aronson Scalable full spectrum cyber determination process
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
MX2015014688A (es) 2013-04-22 2016-02-19 Abbvie Inc Tiazoles y usos de los mismos.
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
MX2021012105A (es) 2019-04-03 2021-11-03 Aligos Therapeutics Inc Compuestos de pirrol.
LT3773558T (lt) * 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
EP4359076B1 (en) 2021-06-21 2025-08-06 SynAct Pharma ApS Phenyl pyrrole aminoguanidine salts and formulations
CN113651673A (zh) * 2021-07-01 2021-11-16 烟台泰和新材料股份有限公司 一种芳烃侧链甲基氯代物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604348D0 (sv) * 1996-11-26 1996-11-26 Wapharm Ab Användning av hydroxyguanidiner
EP1076649A4 (en) * 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
WO2001025192A1 (en) 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
GB0108631D0 (en) * 2001-04-05 2001-05-30 Melacure Therapeutics Ab Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
US6951881B2 (en) * 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
BR0210445A (pt) 2004-08-17
DE60217503T2 (de) 2007-08-09
CA2448356A1 (en) 2003-02-20
EP1414440A1 (en) 2004-05-06
PT1414440E (pt) 2007-04-30
US20090018183A1 (en) 2009-01-15
CA2448356C (en) 2010-04-20
WO2003013509A1 (en) 2003-02-20
DE60217503D1 (de) 2007-02-22
NZ529666A (en) 2006-04-28
EP1414440B1 (en) 2007-01-10
SI1414440T1 (sl) 2007-06-30
JP4450620B2 (ja) 2010-04-14
JP2005504039A (ja) 2005-02-10
DK1414440T3 (da) 2007-05-21
ES2280555T3 (es) 2007-09-16
JP2009242414A (ja) 2009-10-22
CY1106424T1 (el) 2011-10-12
NO20040465L (no) 2004-02-02
IL160181A0 (en) 2004-07-25
KR20040019302A (ko) 2004-03-05
US7186748B2 (en) 2007-03-06
US20040254093A1 (en) 2004-12-16
MXPA04001037A (es) 2004-06-03
AU2002313542B2 (en) 2007-03-22
US20060148798A1 (en) 2006-07-06
US7442807B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
GB0119172D0 (en) Phenyl pyrrole derivatives
IL162388A0 (en) Substituted phenyl derivatives
ZA200309522B (en) Substituted cyclohexane-1-4diamine derivatives
IL160701A0 (en) 3-substituted-4-pyrimidone derivatives
IL160642A0 (en) Pyrrolidinone derivatives
AU2002349297A8 (en) Statin-like compounds
GB0101996D0 (en) Organtic compounds
GB0102668D0 (en) Compounds
GB0130335D0 (en) Compounds
IL158388A0 (en) Novel arylheteroalkylamine derivatives
GB0102665D0 (en) Compounds
HUP0303449A3 (en) Substituted benzofuran-2-carboxamides derivatives
GB0016453D0 (en) Pyrrole derivatives
HUP0401949A3 (en) 4-imidazolin-2-one derivatives
HUP0303186A3 (en) 4-aminobenzopyran derivatives
GB0120818D0 (en) Heterocyclic compounds
HUP0500026A3 (en) N-heteroarylnicotinamide derivatives
IL159064A0 (en) New phenylalkyloxy- phenyl derivatives
EP1364954A4 (en) Dicarba closo DODECARBORANDERIVATE
GB0303366D0 (en) Phenyl pyrrole derivatives
GB0219386D0 (en) Compounds
GB0105098D0 (en) Compounds
SI1427709T1 (sl) 3-substituirani-4-pirimidonski derivati
GB0100183D0 (en) Vovel compounds
GB0119399D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)